Mouse and cell experiments · Evidence assessment
What does the psilocybin mouse survival result mean?
This study cannot establish a human lifespan benefit. More treated mice survived to the study endpoint, but the experiment ended before their full lifespans were observed.
Longevity Lab Report · Assessed · Main study published 2025-07-08
Claim being examined
Psilocybin makes people live longer.
This page assesses the named study and relevant context. It is not a complete systematic review or an individual medical assessment.
What the study measured
- Population
- 58 female C57BL/6J mice, starting at 19 months of age. Separate experiments used cultured human fibroblasts.
- Study design
- Preclinical experiments; mice were allocated to treatment or vehicle groups. Researchers were not blinded.
- What was tested
- Repeated psilocybin exposure in mice; cell experiments used psilocin. There was no human treatment arm.
- Comparison
- Vehicle-treated mice and control cell cultures.
- Duration
- Ten months of mouse follow-up.
- Measured outcome
- Survival at the end of observation; cellular replicative lifespan in separate experiments.
- Observed result
- 24 of 30 treated mice (80%) versus 14 of 28 controls (50%) remained alive. This is a 30 percentage-point survival difference, not 30% longer lifespan.
- Safety limits
- Animal survival does not establish human safety or a usable human regimen.
- Funding and disclosures
- Institutional and public grant support; authors declared no competing interests.
What limits the conclusion?
- One mouse strain and one sex limit generalization.
- All surviving animals were euthanized at the endpoint; average full lifespan was not established.
- Cell division in a dish is not human longevity.
Prior and related evidence
The original paper builds on psychedelic research for other conditions. A 2026 commentary compared the ages at death of 11 prominent psychedelic users with 17 biomedical researchers. Its selected biographical sample, excluded early deaths and uncertain exposures cannot establish a treatment effect or resolve the human-longevity question.
The source list below distinguishes the main study from context.
What this evidence added
The 2025 paper adds a preclinical survival observation worth testing in further experiments.
What it did not establish
There is no human aging treatment result in this paper. No human dose or protocol follows from this explainer.
Still unknown
- Whether independent replication would reproduce the survival result.
- Whether any human aging benefit exists; this study cannot answer it.
- Long-term human safety for an aging intervention.
Does this study address your question?
Optionally compare the population, intervention and outcome. These are study comparisons, not medical advice or a treatment recommendation. Your answers stay on this page and are not saved or included in sharing.
Keep the evidence available
Open the public card to print or shareSaved in this browser only. No account or email required.
Assessment history
· Baseline assessment
First entry in this evidence history. This is a dated assessment of existing research, not a newly published study or a change to a library grade.
Conclusion changed: not applicable — no earlier version in this history.
Sources: mouse · commentary
Sources
- Psilocybin and aged mice (Kato et al., 2025)
Main study · Published 2025-07-08 · Checked 2026-11-15 · DOI 10.1038/s41514-025-00244-x
Primary publisher article and Figure 2 / methods in publisher PDF
- Psilocybin and human longevity (Lerer, 2026)
Context · Published 2026-04-03 · Checked 2026-11-15 · DOI 10.1038/s41514-026-00380-y
Full publisher Matters Arising article; selected retrospective biographies, not an intervention trial
Follow the research in the newsletter
Read the week’s longevity reporting and evidence assessments. Your watchlist and comparison answers are separate from your subscription.
Free. Unsubscribe anytime.
Every grade follows a published rubric. Sponsors do not influence findings or grades.